Indeed, high expressing CD36 attenuated inhibition of breast cancer cell growth by tamoxifen, while inhibition of CD36 synergized tamoxifen-induced cell death (Fig. 5a, d), which is associated with regulation of ERK1/2 activity correspondingly (Fig. 5b, c). Here, MAPK3 is linked to breast carcinoma.